Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs

A Haslam, V Prasad - JAMA network open, 2019 - jamanetwork.com
Importance Immunotherapy checkpoint inhibitors have generated considerable interest
because of durable responses in a number of hitherto intractable tumor types. Objective To
estimate the percentage of patients with cancer in the United States who are eligible for and
respond to checkpoint inhibitor drugs approved for oncology indications by the US Food and
Drug Administration (FDA). Design, Setting, and Participants Retrospective cross-sectional
study performed from June 2018 through October 2018 using publicly available data to …